Markers of human LSCs
| LSC marker . | Leukemia samples . | Mice used . | References . |
|---|---|---|---|
| AML | |||
| CD34+CD38− | FAB M1(1), M4(5), M5(1) | NS | 84 |
| CD34+CD123+ | FAB M1(5), M2(2), M4(7), MDS/AML (2), others (2) | NS | 105 |
| CD34+CD38−CD33+CD13+ | CN-AML (7), CBF-AML (2), MLL-ENL (1), others (2) | NS, NS-B2M | 106 |
| CD34+CLL1+ | AMLs with FLT3-ITD (3) | NS | 107 |
| CD34+CD38−CD96+ | CK-AML(1), CBFB-MYH11(1), PML-RARA(1), AML1-ETO(1), FAB M4(1) | Rag2−/− IL2RG−/− | 108 |
| CD34+CD38+/− | CN-AML (6), MLL-ENL(1), others(2) | NS ± IVIG or anti-CD122, NS-B2M, NSG | 109 |
| CD34−CD38+ | AMLs with NPM1 mutation (16) | NS-B2M, NSG + IVIG | 110 |
| TIM3+ | FAB M1(2), M2(1), M4(1) | NRG | 111 |
| CD34+CD38−CD123+ | AMLs from Fanconi Anemia patients (5) | NSGS | 112 |
| CD34+CD38−CD45RA+ (LMPP-like), CD34+CD38+CD45RA+ (GMP-like) | AMLs spanning FAB subtypes, cytogenetic and molecular categories (100) | NS + anti-CD122, NSG + anti-CD122 or IVIG | 113 |
| variable fractions | CN-AML (4), CBFB-MYH11(2), MLL-AF6(1), others (4) | NSG | 114 |
| variable fractions | CN-AML(8), CBFB-MYH11 (1), CK-AML (2), others (5) | NS + anti-CD122 | 101 |
| CML | |||
| CD34+CD38+/− | chronic phase BCR-ABL+ (9) | NS, NS-B2M | 115 |
| CD34+CD38−CD26+ | chronic phase BCR-ABL+ | NSG | 116 |
| MDS | |||
| CD34+CD38−CD90+CD45RA− | Monosomy 7 (2), low-risk MDS (4) | NSG | 125 |
| CD34+CD38− | MDS 5q (7), MDS RCMD (14), MDS RAEB I (6), MDS-U (2), MDS RARS (2) | NSG, NSGS + patient-derived MSCs | 10 |
| CD34+CD38−CD90+CD45RA− | MDS 5q (2) | NSG | 126 |
| B-ALL | |||
| CD34+CD38− | BCR-ABL[p190](7) | NS | 117 |
| CD34+CD10−, CD34+CD19− | ETV6-RUNX1(3), 11q23(1), others(8) | NS | 118 |
| CD19+ | ETV6-RUNX1(3), BCR-ABL[p210](5), BCR-ABL[p190](5) | NS | 119 |
| CD34+CD38−/low CD19+ | ETV-RUNX1(4) | NS | 120 |
| variable fractions | Childhood ALL(13) including MLL-AF4 and ETV6-RUNX1 | NS+ anti-CD122, NSG | 121 |
| T-ALL | |||
| CD34+CD4−, CD34+CD7− | T-ALL (7) | NS | 122 |
| CD7+CD1a− | Notch1 mutation (3) and others (8) | NS + anti-CD122 | 123 |
| CD7+CD1a− (major), CD7+CD1a+ (minor) | NSG | ||
| CLL | |||
| CD34+CD38−CD90+ | del13q14 (7), others (9) | NSG, NRG | 124 |
| LSC marker . | Leukemia samples . | Mice used . | References . |
|---|---|---|---|
| AML | |||
| CD34+CD38− | FAB M1(1), M4(5), M5(1) | NS | 84 |
| CD34+CD123+ | FAB M1(5), M2(2), M4(7), MDS/AML (2), others (2) | NS | 105 |
| CD34+CD38−CD33+CD13+ | CN-AML (7), CBF-AML (2), MLL-ENL (1), others (2) | NS, NS-B2M | 106 |
| CD34+CLL1+ | AMLs with FLT3-ITD (3) | NS | 107 |
| CD34+CD38−CD96+ | CK-AML(1), CBFB-MYH11(1), PML-RARA(1), AML1-ETO(1), FAB M4(1) | Rag2−/− IL2RG−/− | 108 |
| CD34+CD38+/− | CN-AML (6), MLL-ENL(1), others(2) | NS ± IVIG or anti-CD122, NS-B2M, NSG | 109 |
| CD34−CD38+ | AMLs with NPM1 mutation (16) | NS-B2M, NSG + IVIG | 110 |
| TIM3+ | FAB M1(2), M2(1), M4(1) | NRG | 111 |
| CD34+CD38−CD123+ | AMLs from Fanconi Anemia patients (5) | NSGS | 112 |
| CD34+CD38−CD45RA+ (LMPP-like), CD34+CD38+CD45RA+ (GMP-like) | AMLs spanning FAB subtypes, cytogenetic and molecular categories (100) | NS + anti-CD122, NSG + anti-CD122 or IVIG | 113 |
| variable fractions | CN-AML (4), CBFB-MYH11(2), MLL-AF6(1), others (4) | NSG | 114 |
| variable fractions | CN-AML(8), CBFB-MYH11 (1), CK-AML (2), others (5) | NS + anti-CD122 | 101 |
| CML | |||
| CD34+CD38+/− | chronic phase BCR-ABL+ (9) | NS, NS-B2M | 115 |
| CD34+CD38−CD26+ | chronic phase BCR-ABL+ | NSG | 116 |
| MDS | |||
| CD34+CD38−CD90+CD45RA− | Monosomy 7 (2), low-risk MDS (4) | NSG | 125 |
| CD34+CD38− | MDS 5q (7), MDS RCMD (14), MDS RAEB I (6), MDS-U (2), MDS RARS (2) | NSG, NSGS + patient-derived MSCs | 10 |
| CD34+CD38−CD90+CD45RA− | MDS 5q (2) | NSG | 126 |
| B-ALL | |||
| CD34+CD38− | BCR-ABL[p190](7) | NS | 117 |
| CD34+CD10−, CD34+CD19− | ETV6-RUNX1(3), 11q23(1), others(8) | NS | 118 |
| CD19+ | ETV6-RUNX1(3), BCR-ABL[p210](5), BCR-ABL[p190](5) | NS | 119 |
| CD34+CD38−/low CD19+ | ETV-RUNX1(4) | NS | 120 |
| variable fractions | Childhood ALL(13) including MLL-AF4 and ETV6-RUNX1 | NS+ anti-CD122, NSG | 121 |
| T-ALL | |||
| CD34+CD4−, CD34+CD7− | T-ALL (7) | NS | 122 |
| CD7+CD1a− | Notch1 mutation (3) and others (8) | NS + anti-CD122 | 123 |
| CD7+CD1a− (major), CD7+CD1a+ (minor) | NSG | ||
| CLL | |||
| CD34+CD38−CD90+ | del13q14 (7), others (9) | NSG, NRG | 124 |
CK, complex karyotype; CN, cytogenetically normal; FAB, French-American-British classification system; GMP, granulocyte-monocyte progenitor; LMPP, lymphoid-primed multipotent progenitor; MSCs, mesenchymal stromal cells; NRG, NOD/Rag1−/− IL2RG−/−; NS, NOD/SCID; NS-B2M, NOD/SCID β-2 microglobulin; NSG, NOD/SCID IL2 receptor γ−/−; NSGS, NOD/SCID IL2RG−/− SCF GM-CSF IL-3.